Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating)'s share price was down 3.7% during trading on Tuesday . The stock traded as low as $7.85 and last traded at $7.99. Approximately 30,751 shares traded hands during trading, a decline of 67% from the average daily volume of 92,223 shares. The stock had previously closed at $8.30.
Synaptogenix Stock Down 3.7 %
The business has a 50-day simple moving average of $6.41 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $54.66 million, a price-to-earnings ratio of -3.80 and a beta of 0.91.
Get Synaptogenix alerts:Synaptogenix (NASDAQ:SNPX – Get Rating) last issued its quarterly earnings results on Friday, August 5th. The company reported ($0.54) EPS for the quarter.
Institutional Trading of Synaptogenix
Several hedge funds have recently added to or reduced their stakes in SNPX. Prelude Capital Management LLC lifted its stake in Synaptogenix by 13.9% during the second quarter. Prelude Capital Management LLC now owns 14,364 shares of the company's stock worth $75,000 after purchasing an additional 1,750 shares during the period. Renaissance Technologies LLC bought a new position in shares of Synaptogenix during the 2nd quarter worth approximately $83,000. Finally, Vanguard Group Inc. grew its position in Synaptogenix by 248.9% in the first quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock valued at $1,678,000 after acquiring an additional 154,688 shares during the period. Institutional investors own 9.10% of the company's stock.About Synaptogenix
(Get Rating)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.